BofA warns Fed risks policy mistake with early rate cuts
MedAdvisor Ltd (ASX:MDR), with a market capitalization of $31 million AUD, reported its Q4 2025 earnings, revealing a 34% year-over-year decline in U.S. revenue to $10.1 million AUD. Despite a 52% increase in vaccine-related revenue, the overall financial performance prompted a 2.53% drop in the company’s stock price, settling at $0.077 AUD per share. According to InvestingPro data, the stock has fallen over 84% in the past year and appears undervalued based on Fair Value analysis. The company revised its FY25 revenue guidance to $88 million AUD, projecting a gross margin of 60.8% and an EBITDA loss between $6.5 million and $7.3 million AUD.
Key Takeaways
- U.S. revenue fell by 34% year-over-year.
- Vaccine revenue saw a significant increase of 52%.
- Stock price dropped by 2.53% post-earnings release.
- FY25 revenue guidance revised to $88 million AUD.
- Focus on launching a new patient engagement platform in Q2 FY26.
Company Performance
MedAdvisor’s financial performance in Q4 2025 was mixed, with a notable decline in U.S. revenue. However, the company experienced growth in its vaccine segment, a key area amid ongoing health challenges. The broader U.S. pharmacy market is facing disruptions, with major pharmacy chains under financial strain, affecting MedAdvisor’s operations. The company is adapting by reducing its sales team and restructuring its account management.
Financial Highlights
- Q4 U.S. Revenue: $10.1 million AUD (34% decline YoY)
- Vaccine Revenue: 52% increase YoY
- FY25 Revenue Guidance: Revised to $88 million AUD
- Expected Gross Margin: 60.8%
- EBITDA Guidance: Loss of $6.5 million-$7.3 million AUD
- Cash on Hand: $16 million AUD
Outlook & Guidance
MedAdvisor expects a 15% revenue growth in FY26, driven by the anticipated restart of delayed medication programs and growth in specialty medication revenue. Analyst consensus from InvestingPro suggests a potential upside of 39%, with price targets ranging from $0.06 to $0.12 AUD. Get access to the comprehensive Pro Research Report for deeper insights into MedAdvisor’s growth prospects and financial outlook. The company is also launching a next-generation patient engagement platform in Q2 FY26, focusing on enhancing digital capabilities for pharmaceutical and pharmacy partners.
Executive Commentary
CEO Rick emphasized the importance of engaging patients through pharmacist interactions, stating, "We believe the best opportunity to engage patients in managing their medications continues to be through the pharmacist interaction." He also highlighted the company’s transformation efforts, saying, "We are very focused on transforming the overall business."
Risks and Challenges
- Market Disruption: The U.S. pharmacy landscape is experiencing significant changes, affecting MedAdvisor’s revenue.
- Financial Pressure: Major pharmacy chains are under financial stress, impacting partnerships.
- Regulatory Environment: Increasing pressure on drug pricing could affect profitability.
- Operational Restructuring: Reducing the sales team and restructuring could impact sales momentum.
- Dependence on Vaccine Revenue: Heavy reliance on vaccine revenue may pose risks if demand fluctuates.
Q&A
During the earnings call, analysts inquired about the company’s revenue growth expectations, which are primarily based on the U.S. revenue base. MedAdvisor confirmed exploring potential divestment of its U.S. business but has no immediate plans for cash proceeds. The company is close to achieving cash breakeven, contingent on revenue growth.
Full transcript - Medadvisor Ltd (MDR) Q4 2025:
George, Moderator/Host: So the format for today is for Rick to walk you through the results released this morning, which should take about twenty minutes. This will be followed by a ten to fifteen minute question and answer session, and we aim to finish around 11:15 today. Again, if you’d like to ask a question, please click on the q and a ribbon below and type your question in the box. Alternatively, click on the raise hand icon, and I’ll open the mic at the appropriate time. We’ll endeavor to get through as many questions as we can.
I’d now like to hand the floor over to Rick, who’ll get us started. Thanks, Rick.
Rick, CEO/Primary Speaker, MedAdvisor: Alright. Thanks, George, and, good morning, everyone. I wanna thank, thank you for joining us today, for our fourth quarter f y twenty five update. And, before I get started, I wanna reiterate the welcome to, to Sean Slattery, our incoming CFO, and I welcome him to the, MedAdvisor team. So with that said, if we can turn to some well, we’re on slide three.
That’ll work. So this morning, I’m gonna provide a quick business summary, and then I’m gonna walk through the ANZ and US business, results details. Unfortunately, we have downgraded our f y twenty five guidance, and so I’m gonna walk through some of the details associated with that as well. I’ll provide a quick update on our strategic options review process and what to expect from here and then, spend some time providing a little color on The US landscape at present and, our strategy for best navigating as we as we move forward. And then we’ll finish with a discussion on our f y twenty six priorities and the outlook for the year.
So if we can move to the, next slide. As the subtitle indicates, we’ve continued to experience headwinds through the fourth quarter largely associated with The US business. With that said, we’ve been working diligently in the background, positioning the business to take advantage of some of the tailwinds that I’ll spend some time talking about later in my comments. So let’s review first, key highlights from the quarter and starting with The US business. Although we saw a marked improvement in vaccine related revenue over the prior corresponding period, continued short term headwinds, due to delays in program launches across categories resulted in a notable decline in our US results, and we’ll, go into more detail on that in a few minutes.
Looking ahead, as we look at, f y twenty six, we do have a solid pipeline, which gives us some confidence in, the outlook in the year ahead. And, again, we’ll talk more about that in a few minutes. In Australia, the business continued to perform strongly in the fourth quarter, and the the big news there, being the sale of the ANZ business. So if we look at the group level, very quickly, following the ANZ sale, the receipt of the initial $27,000,000 in proceeds, were utilized to discharge, all of the outstanding debt. And as of the July 7, we were, just over $16,000,000 in cash on hand in the, in the bank.
The strategic options review as is now turned, to focus on The US business in addition to the substantial improvement and programs that we have underway. There is a possible divestment of this business as as the board is considering various options. Further update on this will come along in the quarter, and we’ll talk a little bit more about this in a few minutes as well. As announced in April, Linda Jenkinson, our former chair, decided to step down from the board. She’s been replaced by Kate Hill, who is the interim chair.
And more recently, we announced the departure of our chief financial officer, Ansula Desai. And as many of you know, Ansula has been instrumental over the past, three years in working with myself and the rest of the team, for MedAdvisor through a significant amount of change and transformation, and we’re very grateful for all of the leadership and the support that she’s provided during that period of time. As mentioned a minute ago, Sean Slattery has taken over the CFO and company secretary role as of July 21. And then, again, we’re gonna talk about the f y twenty six oh, I’m sorry, the f y twenty five guidance here in a moment. So if we’ll move to slide 25, very quickly, the Australian business has now been divested, as I mentioned.
So this slide’s really provided for completeness as we as the unit ANZ business did contribute to the fourth quarter results. But it’s suffice it to say that the business experienced a strong quarter benefiting from initiatives over the past few years. I do wanna acknowledge that I’m very pleased the business has moved to a good home, And, Wayne Maranoff, our former general manager of the a and z business, is gonna continue to lead the business going forward as the CEO. So if we’ll turn to the next slide, we’ll go to The US business. Revenue for the quarter, was $10,100,000 AUD, which represents a, 34% decline compared to the prior corresponding period.
This result reflects a softer operating environment and the impact of approximately $4,800,000 in deferred health program revenue. So this is contracted revenue that was to run-in the quarter and, late in the quarter was determined that it would move, into the ’26. On a more positive note, vaccine revenue actually rose 52% year over year with growth driven by pneumococcal, vaccine programs primarily in a in a couple of other categories. In this category, there were several vaccine programs, actually, that were also subject to late quarter delays that affected the full, revenue potential in the quarter. Both general and specialty medication, revenue declined compared to last year.
These declines were largely due to broader industry channel challenges that led to program deferrals in the, in the quarter, and, we will we’ll see the results of that as we look into f y twenty six. There was a case with one specialty program. Budget pressure from that brand, moved that program out as well. And then there were a number of programs that, we have been working on through the year that we’re expecting to not only see run-in the second half, but restart for some programs. Thrive programs contributed to about 40% of quarterly revenue, slightly below the prior year.
This was really the result of some adjustments in our program mix, partially due to, some planning in relation to the transition to our new platform. Gross profit and gross margin were both lower year on year, reflecting the overall revenue decline, but also reflecting allocation of platform costs that started at the beginning of the financial year and have carried on through the first quarter and, in an unfavorable mix on the, product side during the quarter. So lastly, I highlight the pipeline I mentioned a moment ago. It is currently valued at around a $125,000,000, unweighted, which gives us a high level of confidence as we look into, f y twenty six, and we’ll comment towards the end of the towards the end of the presentation. So turning to the guidance, decide a spot despite a, solid pipeline, actually going into the fourth quarter.
Market conditions continue to be challenging, and there were some continued budget pressures. But more so, there were delays in health program activations that were affecting the overall revenue. And, this is I I’ve mentioned this a couple of times. Following the recent finalization of our accounts, but still prior to audit adjustments, we are revising the guidance for f y twenty four down. Revenue for f y twenty I’m sorry.
F y twenty five. Revenue for f y twenty five is now expected to be around $88,000,000 AUD, primarily reflecting the shift in programs that I mentioned earlier. Due to the later than anticipated program starts in the fourth quarter and some updated government guidance on vaccines. As I’ve mentioned a minute ago, approximately $4,800,000 of revenue that was originally expected to drop in the fourth quarter has now been deferred in the ’26. Despite the tailwinds, or, I’m sorry, the headwinds, our overall gross margin is expected to remain stable, at around 60.8% for f y twenty five, consistent with f y twenty four levels.
Finally, the EBITDA guidance is now expected to decline to a loss of around 6,500,000.0 to $7,300,000. So if we move to slide eight on the strategic options, we’ve already covered much of this content, so I won’t dwell on the slide except to say that the ANZ business or the ANZ sale has put the company in a stronger capital position, and the board’s focus has now moved, as I mentioned earlier, to reviewing the path forward for The US business. One option being considered by the board is the possible divestment of this business, and discussions are underway with a number of interested parties. As part of this review, the board is considering capital management options, including a possible capital return, and we plan to provide further updates during this quarter and wrap up the review by the end of the end of the year. So now if we spend a few minutes on The US business, if we’ll go to the next slide, I’ll spend a few minutes talking through these different categories.
As I’ve mentioned previously, we’re seeing trends in The United States that are significantly reshaping the pharmacy and pharmaceutical, landscape. Starting with the pharmacy industry in the upper left hand corner, there is a shift toward what we call direct to consumer models, which is reshaping patient engagement type programs, and it is lengthening sales cycles in some situations. Investment is investment from the pharmaceutical manufacturers is focused on specialty medications and disease management, and, fragmented channels, across spend in the pharmaceutical organizations is driving a more significant demand and more focus on, clear return on investment. And while, while we are seeing vaccine programs or vaccine funding, remaining important with these organizations, because of public policy changes, we are seeing some level of market uncertainty, but there definitely will be spend in these categories. In the pharmacy sector, major US pharmacy chains like CVS and Walgreens, are under significant financial pressure, closing stores and shifting to new digital first strategies, which play to our advantage, but they are experiencing significant, pressures on their margins.
And we’ve seen some of this most recently with the privatization of Walgreens through a private equity transaction and Rite Aid’s recent bankruptcy. There’s also the challenge with digital disruptors in the markets such as Amazon who are raising consumer expectations. But at the same time, we’re seeing vaccine administration be a key driver for pharmacy store traffic and profitability across different categories of vaccinations such as flu, RSV, COVID, shingles, and, in particular, pneumococcal vaccines. The competitive environment has become more fragmented with the with the rise of the number of niche digital vendors, which is challenging our ability as we’re working with the DTC brand groups in maximizing brand budget allocation to the, MedAdvisor programs. We’re also seeing agencies are, who are representing the brands are becoming much more cautious.
The planning cycles are getting somewhat longer. And as I mentioned a minute ago, the focus on return on investment is increasing significantly. And in in addition to all of this, you know, we have reduced our sales team significantly, and so our infill presence is much lower than it has been in the past, which is affecting our brand and agency engagement, and I’ll talk about that more in a minute. So finally, on the government side, regulatory pressure around drug pricing and, direct to consumer oversight is increasing, brand caution, brand pharmaceutical brand caution, and market uncertainty. Changes to vaccine coverage and funding combined with the recent vaccine administrate or advisory committee upheaval from RFK junior have impacted confidence and trust across the industry.
So this in this uncertainty is impacting not only pharmacy readiness, but timing of brand investments. So in summary, you know, it’s a it’s a very dynamic and somewhat disruptive environment. But with the right strategy, we believe that there’s still significant opportunity even in the face of, of these challenges. So if we’ll turn to the next slide. So in the face of, this market disruption, we’re actively, resetting our commercial strategy to unlock growth going into f y twenty six.
Our business development team is, is being rebuilt to strengthen brand engagement, expand our account penetration, and establish new agency relationships. So there is a renewed focus on agencies, and the expected increase in our business development capacity going into f y twenty six in the particularly in the first half, we believe will help support faster pipeline conversion as well as, position us well for a, very strong second half. So we’re also tightening our sales qualification, criteria to prioritize high conversion brand funded opportunities. So in relation, we’re expanding engagement with some of our top pharmaceutical sponsors we’ve been working with for a number of years, including Pfizer, GSK, Merck, Novo Nordisk, Dexcom, and others. So the intent here is really to strengthen our position and, gain a higher share of wallet as, as we build out our sales team as well as our account management group.
So operationally, we’ve, restructured our account management team under our customer success leadership to improve execution and retention. Dedicated team is now in place and focused on program delivery, so there’s an operational aspect to our account management function. And there’s also a coordinated effort with our business development team on client facing, relate related activities around, relationship development, program renewals, and upsell of, of other services and opportunities. So we’re taking we’re also taking our insights from the fourth quarter, to better anticipate client delays and bolster program readiness. We did experience a number of delays that were not expected moving revenue from fourth quarter into the ’26, and the, efficiency of getting these programs through their process and launched is a challenge in managing that, not only with the pharmaceutical manufacturers, but ensure we’re as efficient as possible, within our own operations.
So we’re also looking very closely at aligning our channel delivery and program design so that we’re matching our retail customers and pharmacies ex pharmaceutical partners’, expectations. Getting the right alignment helps us to ensure programs getting in to to the, into production faster, and it also streamlines the sales cycle. In addition to that, we’re continuing to focus on our in pharmacy print solution. It continues to be the foundation. We have a much stronger moat around that particular offering, and it provides the most reach for our market.
And then we can provide surround sound type capabilities with our digital function as we expand our, pharmacy network capabilities. And then lastly, we’re very excited to launch our next generation engagement platform that’s going to empower pharma and pharmacy partners to more easily build tailored data driven patient engagement programs faster and at a lower cost. So if we’ll move to slide 11, we can now look at, our f y twenty six priorities in the outlook. So key priority, as I’ve already, mentioned a couple of times, is for us to complete the US commercial team restructure alongside with scaling our customer success operations. These changes are critical to improving execution and ensuring that we can better serve our clients across The US market.
In q two, f y twenty six, we’re set to launch the next generation of our patient engagement platform that we’ve talked about quite a bit up to this point. This is a significant major milestone for us and is gonna be a key driver for expansion of our digital capabilities with our pharma and pharmacy partners. We’re also strengthening and expanding our US pharmacy network relationships, to reduce execution risk and build greater resilience into our program delivery model. This will support more consistent performance and better program outcomes across the board. It’s extremely important to the, future growth of the business.
Transformation three sixty will remain a core focus throughout the year as we continue to streamline operations, redesign business processes, and manage organizational change, much more effectively. And then another important milestone, again, will be the completion of our strategic options review process, which we will provide more updates on that here in the near future. So turning to the outlook on the right side, from a market perspective, you know, we’re entering f y twenty six with a strong pipeline, as I’ve mentioned a couple of times. Based on this, you know, we’re confident in delivering a 15% revenue growth in f y over f y twenty five in f y twenty six. While we expect vaccine related revenue to be below prior year levels, we do anticipate the restart of a number of delayed general medication programs into the first in the first half of the year.
And in addition, we have, good visibility to expansion of our specialty medication revenue, and we expect that to grow meaningfully through the, through the year. So, importantly, we’ve been focused on reducing our cost base, particularly through the ’25, and, we’ll continue to focus on that, as I’ve mentioned, in launching our our new platform. But in relation to all of this and the cost reductions that we’ve done in February and April time frame of this year, we do expect that f y twenty six operating expense to be in The United States to be down around 10% from f y twenty five, and it’ll be down around close to 30% from f y twenty four. So with that, I think that concludes my statements for, the presentation at least. I appreciate, everyone’s time, and I will hand it back to George to see if there might be any questions.
Thanks, George.
George, Moderator/Host: For that, Rick. Yep. There are a few questions. Just as a reminder, if you would like to ask a question, please click on the q and a box in the ribbon below and type your question into the box. Alternatively, you can click on the raise hand, and I can open your mic at the appropriate time.
Rick, first question says, are you going to spend the the it says our cash, but I guess the proceeds of the the sale in The United States.
Rick, CEO/Primary Speaker, MedAdvisor: No. The proceeds from the the net proceeds from the sale after discharging the, the debt have been, have been set aside, and the intent at this point is not to use those proceeds in The United States. This would include the expectation of the holdback that is yet to come. That’s the additional $8,000,000 AUD that we would expect to come in, before the end of the calendar year f y of calendar year 2025.
George, Moderator/Host: Yep. Thanks, Rick. Next question. If you divest The US business, what is left? And does the company become an ASX shell?
Rick, CEO/Primary Speaker, MedAdvisor: If there’s a that that’s a good question. If there’s a divestiture of The US business, There are several different options that are being reviewed with our advisers in Australia, and Sean is is involved in that, as we speak to, determine, you know, what that, structure might look like, but there’s no specific answers to that question at this point in time. And it’s not a given that, by the way, that there will be a divestiture. That is an option that’s being reviewed.
George, Moderator/Host: Thank you. Next question. I calculate The US revenues to be around AUD 63,000,000 for FY ’25 and gross margin at around 33 mil based on a margin of 53%. What is the cost base of The US business now? And is that margin expected to improve in FY twenty six?
Rick, CEO/Primary Speaker, MedAdvisor: So the the revenue sounds correct. I’m I’d I’d have to Sean, I’d have to come to you, you know, help on this if you if you have the data. If you don’t, we may have to come back.
Sean Slattery, CFO, MedAdvisor: No. I’ll have to come back to, the person asking the question. I’ll take this question on notice just because I don’t have it readily available.
George, Moderator/Host: Alright. That’s fine. Thank you. We’ll we’ll come back to you on that one.
Rick, CEO/Primary Speaker, MedAdvisor: Yeah.
George, Moderator/Host: With all the changes impacting The US business, are you still expecting revenues to be skewed to the first half twenty six? So or is that or has that changed?
Rick, CEO/Primary Speaker, MedAdvisor: Because there is still some emphasis on vaccine related programs and an expectation that vaccines will continue to be a part of the business, maybe not at the same scale. There will be some skewing towards the the first half, but probably not to the same scale as what we’ve seen in the past.
George, Moderator/Host: Alright. Great. Next question. Do you think that your management team has lost their focus on how pharmacy retail wants to interact with pharma based on your pricing model and objectives?
Rick, CEO/Primary Speaker, MedAdvisor: Could you repeat that question?
George, Moderator/Host: Yeah. Sure. Do you think that your management team has lost their focus on how pharmacy retail wants to interact with pharma based on your pricing model and objectives?
Rick, CEO/Primary Speaker, MedAdvisor: So there’s probably several different elements to that question. First of all, the management team is continually assessing the the environment and the, you know, the nature of how a pharmacy, that’s part of the question, would like to engage with pharma is definitely something we’re continuing to evaluate. Now keep in mind that whether you’re a pharmacy in The US or you’re a pharmacy in Australia, the pharmacies are always in in interacting with pharma in various ways, sometimes through a wholesaler because they’re working on distribution, sometimes with the media side of a of a manufacturer because they do in store advertising as an example. This is more physical advertising in the store. So this could be you know, this is not digital.
This is not technology. So we are continually working with the retail pharmacies to determine the best way to be their partner to help engage their customers with pharma sponsored kinds of communications and drive awareness and adherence of different kinds of program of, of different kinds of products. So that’s that’s the key. Now the pricing issue is different. So the question might might be in relation to vaccines as an example, which is an area that we’re taking a look at.
Vaccines has been about 30 to 40% of our revenue, and I would expect it to continue to be in the 30% range even going forward. However, the way that we run those programs at in the pharmacies on behalf of pharma, that that model could change over time. Now that’s that’s for a variety of reasons. That’s not just because of the pharmacy. That’s also because of the government and regulatory issues.
So we have to balance what the pharmacies are looking for with pharma and the pricing models and structure for these programs that are compliant with regulations. So the answer to the question is not easy, assuming I’m understanding it correctly, but it is something that is core to our business, and we have to continue to evaluate.
George, Moderator/Host: Alright. Thanks, Rick. Next question. Given the uncertainty in The US business, does it make sense at this stage to consider a capital return, especially if The US business has not been cash flow positive for many quarters, and the 16,000,000 in cash provides the business with some flexibility?
Rick, CEO/Primary Speaker, MedAdvisor: The that’s a part of the analysis that’s that’s being done relative to the capital management strategy. And I would say, you know, at this point, given the you know, where the business has come from, our strategic options evaluation process in combination with the processes to look at opportunities in The US and Australia while we’re also running the business. We’ve gotta, know, continue to look at, you know, all of those components, and that particular point is a is a valid point and kinda plays to the question on the appropriate utilization of available funds. And does that make sense for the business, but is it also, in alignment with shareholder expectations? So we’ve gotta we we’ve gotta work through that, particularly in the next thirty to sixty days.
George, Moderator/Host: Right. Thank you. Next question says, you say 15% revenue growth. How much is that in dollars? I think the question is probably around when you refer to 15% on up on f y twenty five, is that the the reported f y twenty five number or The US portion of the the revenue?
Rick, CEO/Primary Speaker, MedAdvisor: The 15% growth would be off of The US revenue base.
George, Moderator/Host: Okay.
Rick, CEO/Primary Speaker, MedAdvisor: So
George, Moderator/Host: Thank you.
Rick, CEO/Primary Speaker, MedAdvisor: Take that number times 1.15, and you gotta or times 1.15 if you just want the net. Yeah.
George, Moderator/Host: Right. Thanks. Next question. Can you clarify the senior exec KPIs for FY twenty six? Is there a reference to the sale of The US business?
Rick, CEO/Primary Speaker, MedAdvisor: They’re the we’re in The because of because of the process we’re going through, we’re in the early stages of finalizing the KPIs in FY twenty six. The KPIs are focused on are focused on revenue growth, margin protection, product expansion, deployment of our new platform, etcetera. Those are kind of the categories. The the transaction if there is a transaction to be had in The United States, that’s somewhat of a separate conversation, a separate set of objectives.
George, Moderator/Host: Thank you. I’m not sure you’re be able to answer this one, but what’s the expected EBITDA in f y twenty six?
Rick, CEO/Primary Speaker, MedAdvisor: I would say at this point, we we’ve got we’re working through you’ve got an idea of what our focus is on on revenue, and there’s a good indication of where we’re at relative to OpEx. So I’ll probably just leave it at that. I think we’ve provided so I think I think we provided the metrics to be able to to make some determinations there.
George, Moderator/Host: Yeah. Next question. It says, is the business cash breakeven?
Rick, CEO/Primary Speaker, MedAdvisor: The the biz it it it varies by time you know, over time. At this point, given the level of revenue, as we brought down the cost basis, we’re very close. But it but it’s it’s dependent upon the, you know, the the revenue the revenue growth.
George, Moderator/Host: Okay. Thanks. Back to this growth, it says, looking at the guidance, is revenue growth including the 4,800,000 deferral? And then it goes on to ask, is that 15% based on the group number or the US number which you answered earlier? But I guess back to the first part of the question, does the revenue guidance include the 4,800,000 deferral?
Sean Slattery, CFO, MedAdvisor: Yeah. So it’s deferred revenue. We’ve recognized across FY ’26.
George, Moderator/Host: Right. Thank
Rick, CEO/Primary Speaker, MedAdvisor: you. You’re talking about the FY ’25 guidance? What are you talking about?
George, Moderator/Host: Is there
Rick, CEO/Primary Speaker, MedAdvisor: Or your ’26 guidance.
George, Moderator/Host: It says looking at the guidance, is revenue growth no. It’s all about the 15% revenue growth including the 4,800,000 deferral.
Rick, CEO/Primary Speaker, MedAdvisor: Yes. It’s in the it’s it’s yes.
Sean Slattery, CFO, MedAdvisor: That will form part of f y twenty six revenue.
George, Moderator/Host: Yeah. Correct. Thank you. Next question. How much of the 8,000,000 holdback are you expecting to realize?
Rick, CEO/Primary Speaker, MedAdvisor: At this point, we’re we’re working towards realizing the entire amount unless told otherwise.
George, Moderator/Host: Given the stated outlook in the presentation for FY ’26, you should be able to state state the outlook sorry. This you should be able to state the outlook. I think he’s just saying given given your outlook statement, you should be able to provide revenue profit and EBITDA guidance. It’s not really a question. It’s more of a statement.
Rick, CEO/Primary Speaker, MedAdvisor: If not, I’ve we’ve given the guidance that we’re planning to give at this point.
George, Moderator/Host: That looks like it’s all the questions at this point in time. So what I might do is I might just hand it back to you, Rick, for any closing remarks you might wanna make.
Rick, CEO/Primary Speaker, MedAdvisor: Okay. Yeah. No. I I thanks, George. And I I appreciate everyone taking the time to spend with us this morning.
We have been on quite a quite a journey over the, over f y twenty five, and, we’ve experienced a number of challenges. With with that said, we are very focused on transforming the overall business and going into f y twenty six, you know, we remain very confident, that the best opportunity to engage patients in managing their medications continues to be through the pharmacist interaction with that patient. So we believe we’re in the right space. We believe we’re making the right investments relative to our new platform. We’re bringing down the cost basis.
We’re restructuring our commercial team. We’re building for, success and for turning this business around in f y twenty six. So, I appreciate everybody’s time today. I appreciate everybody’s patience with with all of the change that’s been going on through this business. It’s been, been a significant challenge.
There’s no question. We’re we’re we do believe in the base fundamentals of the business and the direction, and we’re in the right place. We have got to execute at this point, and, we’ve got to convert our pipeline and, bring value to our customers, and that’ll turn into value to our shareholders. So I appreciate, again, the time. And, George, I will turn it back to you and, to wrap things up.
And thanks, Sean, for joining us.
George, Moderator/Host: Yeah. Yeah. Thanks, Rick, and thanks, Sean. I’ll also add my thanks to everyone for joining us today. That wraps up the proceedings, and I’ll invite you all to now disconnect.
Have a nice day.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.